|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.98/-1.26
|
企業價值
33.67M
|
資產負債 |
每股賬面淨值
-0.71
|
現金流量 |
現金流量率
--
|
損益表 |
收益
4.85M
|
每股收益
0.30
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/09 18:44 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type offemale sexual dysfunction. |